IMR Press / FBL / Volume 5 / Issue 4 / DOI: 10.2741/begleit

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Clinical applications of quinone-containing alkylating agents
Show Less
1 Manitoba Institute of Cell Biology, CancerCare Manitoba and the Departments of Internal Medicine and Pharmacology and Therapeutics, University of Manitoba, Winnipeg, Canada
Academic Editor:Peter Gutierrez
Front. Biosci. (Landmark Ed) 2000, 5(4), 153–171;
Published: 1 November 2000
(This article belongs to the Special Issue Mechanisms of action of quinone-containing alkylating agents)

Quinone-containing alkylating agents are a class of chemical agents that have received considerable interest as anticancer drugs. These agents contain a quinone moiety that can be reduced and an alkylating group that can form covalent bonds with a variety of cellular components. The oxidation state of the quinone element can modulate the activity of the alkylating element, and reduction of the quinone is required for activation of the alkylating activity of many of these agents. The quinone element may also contribute to the cytotoxic activity of quinone-containing alkylating agents through the formation of reactive oxygen species during redox cycling. The natural product, mitomycin C, has been the most widely used quinone-containing alkylating agent in the clinic, but other quinone-containing alkylating agents like porfiromycin, diaziquone, carbazilquinone, triaziquone and EO9 have also been used in the clinic for the treatment of cancer. In addition, many other quinone-containing alkylating agents have been tested in preclinical studies and the development of new agents is being actively pursued. This chapter describes the current and past clinical uses of these agents in the treatment of cancer and discusses new agents that are currently in clinical trials.

Quinone Agents
Alkylating Agents
Back to top